Dr. Gyungah Jun has recently received a subaward agreement from the University of Southern California for a U01 award, titled “Ultrascale Machine Learning to Empower Discovery in Alzheimer’s Disease Biobanks.” For this grant, Dr. Jun will serve as a PI for the Genome Guided Drug Discovery Core and will contribute her expertise regarding aspects of human genomic guided drug discovery and biomarker development to this project linking to AD drug discovery. She will be responsible for data interpretation and analysis, and general project and personnel management at the Core in BUMC. She will also participate in the large consortium related activities for this project.
Dr. Lindsay Farrer & Dr. Rhoda Au awarded new grant to establish the Framingham Heart Study Brain Aging Program
Dr. Lindsay Farrer & Dr. Rhoda Au have been awarded a new grant from the NIH that will help establish the new Framingham Heart Study Brain Aging Program (FHS-BAP). The FHS-BAP will concentrate on a number of functions, including continued study of FHS participants for dementia, revitalizing the brain donation program & brain bank, establishing a platform to promote Data Sharing, and more!
Study Finds Novel Molecular Therapeutic Target for Colon Cancer
RICTOR/mTORC2 pathway inhibition could make chemotherapy more effective
Study finds novel molecular therapeutic target for colon cancer
Researchers identify new pathway as biological target for colon cancer
Dr. Huiping Zhang receives BU CTSI grant to study the epigenetic mechanism of cocaine use disorders (CUDs)
Dr. Huiping Zhang receives BU CTSI grant to study the epigenetic mechanism of cocaine use disorders (CUDs). He and his collaborator Dr. Vidhya Kumaresan will investigate cocaine use/withdrawal induced microRNA (one type of epigenetic markers) expression alterations in the brain’s reward circuit (e.g., the nucleus accumbens) using a translational rat model of incubated drug craving (i.e., extended access to cocaine with prolonged abstinence and consequent increased craving). It is expected that cocaine withdrawal responsive microRNAs (or their target genes) could be potential biomarkers for CUDs and novel therapeutic targets.”